Kiora Pharmaceuticals Said Co And Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement For KIO-201; Amendment Eliminates $4.75M In Near-term Milestones Kiora Would Have Owed To Sentrx
Portfolio Pulse from Charles Gross
Kiora Pharmaceuticals and Sentrx Animal Care have amended their existing manufacturing licensing agreement for KIO-201, eliminating $4.75 million in near-term milestones Kiora would have owed to Sentrx.

June 15, 2023 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kiora Pharmaceuticals (KPRX) amends its manufacturing licensing agreement with Sentrx Animal Care, eliminating $4.75 million in near-term milestones.
The amendment of the manufacturing licensing agreement between Kiora Pharmaceuticals and Sentrx Animal Care eliminates $4.75 million in near-term milestones that Kiora would have owed to Sentrx. This is a positive development for Kiora Pharmaceuticals as it reduces their financial obligations, potentially improving their short-term financial position and making the stock more attractive to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100